MedCare Investment Funds
3322 W End Ave, Ste 1100, Nashville, Tennessee, 37203, United States
Overview
MedCare Investment Funds is a venture capital firm specializing in seed, start-up, early venture, mid venture, and late venture financing. It seeks to invest in companies in any stage of development. The firm seeks to invest in companies involved in healthcare and medical services. The firm may act as the lead investor in capital syndications. MedCare Investment Funds was founded in 1991 and is based in Nashville, Tennessee with an additional office in San Antonio, Texas. It operates as a subsidiary of Healthcare Investment Group.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Refocus Group
Led · Equity · May 2016
Refocus Group develops the VisAbility Micro-Insert System, an investigational scleral implant intended to restore near vision without compromising distance vision or altering the cornea or natural lens. The VisAbility Procedure inserts four micro-thin implants just below the scleral surface as an outpatient procedure with topical anesthesia. Refocus completed enrollment in a Phase 3, prospective multicenter trial of 360 subjects aged 45–60 across 13 U.S. clinical sites; the FDA granted a 12-month follow-up for approval rather than the usual 24 months. Given the trial history and enrollment completion, the company expects to submit for FDA premarket approval in 2017 and prepare for commercialization. Refocus recently secured $15 million in new financing to support trial completion and the premarket approval process. Don Phillips of WP Global Partners will join the Refocus board to assist in guiding the company. The company is headquartered in Dallas.
- Seno Medical Instruments
Led · Series C · Feb 2014
Seno Medical Instruments develops opto-acoustic imaging tools for breast cancer diagnosis, combining light-in/sound-out technology with conventional ultrasound in its Imagio® device. Imagio provides a blood map in and around suspicious breast masses without ionizing radiation or injectable contrast agents. The company is led by CEO Janet Campbell and is based in San Antonio, Texas. Seno is conducting a U.S. Pivotal Study of Imagio and is pursuing CE Mark approval in Europe, targeting approval by the end of Q1 2014. Financially, the company secured Series C equity financing to support those clinical and regulatory activities.
Team
No current team members are available.